Connect with us

Life Sciences

Wellbeing Digital Announces Resignation of Directors

Wellbeing Digital Sciences Inc. (NEO: MEDI | OTC: KONEF | FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation…

Published

on

This article was originally published by Psychedelic Invest

Wellbeing-Digital-Sciences

Wellbeing Digital Sciences Inc. (NEO: MEDI | OTC: KONEF | FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that James Henning and Steven Inglefield have stepped down as directors of the Company

“James has served on the Wellbeing board of directors since the Company’s inception. Overtime he has made many contributions to the success and growth of the Company, drawing on a wealth of experience gained over a long and successful business career.”

Najla Guthrie, CEO of Wellbeing

“Steven has served as a Director of the Company as well as its Chief Operating Officer since the purchase of IRP Health Ltd. (“IRP”) and made considerable contributions during his tenure. With the Company’s decision to divest IRP Health Ltd. (“IRP”), Steven leaves to focus on IRP’s expanding growth.”

Najla Guthrie, CEO of Wellbeing

“On behalf of the board of directors, the management team and our shareholders, I thank James and Steven for their contributions and wish them the best in their future endeavours,” added Najla.

About Wellbeing Digital Sciences

Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. Its mission is supported by a network of North American clinics that provide forward-thinking therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development.

contract research
therapeutics
healthcare

Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Markets

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending